DPK guidance withdrawn
This article was originally published in The Tan Sheet
Executive Summary
FDA is withdrawing its draft guidance on dermatopharmacokinetics based on input from the public, agency advisory committees, FDA announces in May 17 Federal Register. Comments raised "substantial doubt" regarding the adequacy of DPK to assess bioequivalence of topical dermatological drugs because such products address a variety of diseases on different parts of the skin, not just stratum corneum, FDA explains. Reproducibility of the method between labs also was questioned. Agency plans to "explore the development of new methods and improvements in current methods" for documenting bioequivalence of topical dermatologicals...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.